Clinical Trial

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Name: Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function — clinical trial record (NCT07169825)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Protocol Amendment History 2 changes

critical Phase changed: not applicable -> Phase 4 2026-08-05

critical Recruitment opened 2026-04-03

Trial Details

NCT Number	NCT07169825
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: GE Healthcare
Conditions	Lu-177 PSMA
Enrollment	25 participants
Start Date	2026-03-30
Primary Completion	2026-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-04